<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580473</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0118-SATURNO II</org_study_id>
    <nct_id>NCT03580473</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification</brief_title>
  <official_title>Phase II, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Saturno II association on the
      control of ocular inflammation post-phacoemulsification
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of ocular inflammation post-phacoemulsification as evaluated though the presence of cells in the anterior chamber</measure>
    <time_frame>16 days</time_frame>
    <description>The inflammation will be evaluated though the presence of cells in the anterior chamber. For this, the number of cells per high-power field in the anterior chamber was counted and recorded on a scale where 0 indicates ≤ 5 cells, 1 = 5 to 10 cells, 2 = 11 to 20 cells, 3 = 21 to 50 cells, and 4 corresponds to ≥ 50 cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Ocular Inflammation</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>SATURNO II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigadexa®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SATURNO II association</intervention_name>
    <description>opthalmic solution, 4 times a day</description>
    <arm_group_label>SATURNO II</arm_group_label>
    <other_name>Legrand association</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigadexa®</intervention_name>
    <description>opthalmic solution, 4 times a day</description>
    <arm_group_label>Vigadexa®</arm_group_label>
    <other_name>Moxifloxacin Hydrochloride 5mg/mL + Dexamethasone Disodium Phosphate 1mg/mL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes, aged 18 years or more;

          -  Participants presenting the diagnosis of cataract with indication for surgery by the
             phacoemulsification procedure;

          -  Participants who undergo surgery in only 1 eye at a time;

          -  Participants with intraocular pressure (IOP) ≤ 20 mmHg;

          -  Signed consent.

        Exclusion Criteria:

          -  Used non-steroidal anti-inflammatory drugs or topical steroids or systemic inhalers
             within 21 days prior to randomization of the clinical trial;

          -  Performing the surgery for the second time, to correct the previous procedure or to
             change the lens;

          -  Decompensated glaucoma or ocular hypertension with IOP above 21 mmHg;

          -  Active ocular infectious diseases;

          -  History hypersensitivity to the active ingredients used in the study;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  History alcohol abuse or illicit drug use;

          -  Any clinical and laboratory findings that, in the judgment of the investigator, may
             interfere with the safety of research participants;

          -  Participation in clinical trial in the year prior to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B.Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allegisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13.084-791</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Iyeyasu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

